Life Healthcare Group Holdings (LHC) has delivered its summarized group results for the year ended September 30, 2025, showcasing solid revenue growth in its core South African operations despite complex accounting adjustments. The company’s financial narrative is currently defined by the spectacular payoff from its strategic divestiture of a high-tech diagnostic business, resulting in significant capital returns to shareholders.

The group’s core underlying performance metric, normalised earnings per share (NEPS), increased by 10.1%, reaching 100.3 cents (up from 91.1 cents in 2024). Furthermore, revenue from continuing operations grew 6.0% to R25.1 billion, reflecting the strength of the underlying business.

The Extraordinary Return on Investment

The major financial event of the year was the disposal of Life Molecular Imaging (LMI), which was sold to the British subsidiary of the American pharmaceutical giant, Lantheus. This deal has the potential to yield up to $755 million for Life Healthcare.

LMI, which focuses on developing and commercializing molecular imaging agents for PET-CT diagnostics, was acquired by Life Healthcare in 2018 for the nominal sum of just $5. Since the acquisition, LHC invested around $100 million into nurturing the research and development organization, headquartered in Berlin, which focused on Alzheimer’s diagnostic field pioneers. The business became highly relevant following the FDA approval of Alzheimer’s therapy in January 2023.

The final deal comprised an upfront payment of $355 million (approximately R6.3 billion to R6.475 billion). LHC is also entitled to potential earnouts of up to $400 million, contingent on future sales of LMI products through to 2034.

Following the successful sale and the prior disposal of Alliance Medical Group (AMG), Life Healthcare has returned substantial capital to shareholders. Total funds distributed for the year ended September 30, 2025, including special dividends, amounted to R4.3 billion. A special dividend of R2.35 per share (R3.4 billion) was paid in September 2025 from these proceeds. The final cash dividend declared was 35.0 cents per share, an increase of 12.9% compared to the prior year.

Accounting Hits Mask Operational Strength

Despite the solid underlying performance, Life Healthcare’s statutory earnings were significantly impacted by accounting rules related to its divestiture strategy. The group recognized a substantial, non-cash accounting adjustment of R2.9 billion, representing a fair value adjustment to the pre-existing contingent liability owed to Piramal, the original owners of LMI.

Due to this charge, statutory headline earnings per share (HEPS) from continuing operations dropped by more than 100%. Total earnings per share (EPS), including continuing and discontinued operations, decreased by 20.0% to 263.0 cents. Impairments of R211 million were also recognized in relation to underperforming units.

LHC CEO Peter Wharton-Hood emphasized that the disciplined capital management and returns to shareholders reflect the fundamentals of the business remaining resilient, offering investors clearer visibility into a stable, well-positioned organization now focused on continuing operations.

Strategic Focus and Future Growth

With the disposal of international assets, Life Healthcare is now streamlined and focused on its Southern African acute hospitals and complementary services businesses, which include 48 acute hospitals and 71 healthcare facilities.

The group maintains a strong financial position, reporting a net debt to normalized EBITDA of 0.01 times (well below its covenant limit of 3.5 times), reflecting a formidable balance sheet and financial flexibility.

LHC has approved capital expenditure of approximately R2.5 billion for FY2026 to support strategic growth initiatives. These include the continued building of the 140-bed Life Paarl Valley Hospital, expected to open in FY2027, as well as adding 89 acute hospital beds, 40 acute rehabilitation beds, and 20 renal stations to its existing portfolio.

Furthermore, the diagnostics business is expanding with three new PET-CT sites, and two cyclotrons built in partnership with Africa X-Ray Industrial and Medical Proprietary Limited (Axim) are expected to become operational after completing regulatory approval. LHC retains the rights to manufacture, commercialize, and distribute LMI products within Africa.

Sector Dynamics: Concentration and NHI Uncertainty

Life Healthcare’s results come amidst a challenging and highly concentrated South African healthcare environment. The private hospital market is dominated by three major groups—LHC, Netcare (NTC), and Mediclinic—which collectively account for 83% of national private facility beds.

A major headwind impacting investor sentiment and valuation is the uncertainty surrounding the National Health Insurance (NHI) Bill. This uncertainty has been blamed for driving capital away from the sector, causing healthcare stocks to trade at lower multiples than in other markets.

LHC management supports the ultimate ambition of NHI, believing that private healthcare must play a role in delivering care to more South Africans, especially since the government cannot accomplish this alone. However, there is a strong call for constructive dialogue, as opposed to “rumor mongering and fear mongering,” which only serves to destabilize the sector and discourage investment.